Controversies and new approaches to treatment of Langerhans cell histiocytosis

R. J. Arceci, M. K. Brenner, J. Pritchard

Research output: Contribution to journalArticlepeer-review

109 Scopus citations


There continues to be genuine ambivalence as to whether Langerhans cell histiocytosis (LCH) is a primary neoplastic or immunodysregulatory disorder. Treatment strategies have moved from one camp to the other depending upon the most current alleged successes or failures. This has been particularly true for patients who fall outside of the sphere where treatment is minimal or where known treatment approaches are clearly beneficial. However, there is growing evidence that LCH is both the result of clonal proliferation of Langerhans cells and the immunologic consequence of increased cellular activation. This new knowledge should be the basis for the development of new therapeutic approaches for patients with LCH and its complications.

Original languageEnglish (US)
Pages (from-to)339-357
Number of pages19
JournalHematology/Oncology Clinics of North America
Issue number2
StatePublished - 1998

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Controversies and new approaches to treatment of Langerhans cell histiocytosis'. Together they form a unique fingerprint.

Cite this